Serum thymidine kinase 1 activity as a prognostic biomarker in dogs with chemotherapy-treated diffuse large B-cell lymphoma

Simple item page
dc.contributor.authorZaidi, Bushraen
dc.contributor.authorMukhopadhyay, Abhijiten
dc.contributor.authorRamos-Vara, Jose A.en
dc.contributor.authorDhawan, Deepikaen
dc.contributor.authorRuple, Audreyen
dc.contributor.authorChildress, Michael O.en
dc.date.accessioned2023-03-27T19:47:24Zen
dc.date.available2023-03-27T19:47:24Zen
dc.date.issued2023-01-18en
dc.date.updated2023-03-27T19:25:57Zen
dc.description.abstractDiffuse large B-cell lymphoma (DLBCL) is frequently treated with chemotherapy incorporating cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), which induces remission in 80% to 95% of cases. However, not all dogs derive meaningful benefit from CHOP, and prognostic factors for dogs with DLBCL are poorly defined. Serum thymidine kinase 1 (TK1) activity, a marker of tumour cell proliferation, has shown promising initial results as a prognostic biomarker in dogs with multicentric lymphomas. The purpose of this study was to determine if baseline serum TK1 activity is associated with clinical outcome in dogs with CHOP-treated DLBCL. Baseline serum TK1 activity was measured in banked sera from 98 dogs with CHOP-treated DLBCL using a commercially available ELISA kit. Data on other potential prognostic factors were abstracted retrospectively from electronic medical records. Multivariable statistical methods were used to identify associations between TK1 and other potential prognostic factors with progression-free survival (PFS) and attainment of complete remission. TK1 activity at baseline was not associated with PFS (p =.299) or attainment of complete remission (p =.910) following CHOP chemotherapy. Of the other prognostic factors analysed, only purebred (vs. mixed breed) status (HR 8.81, 95% CI 1.68–46.30, p =.010), attainment of complete (vs. partial) remission (HR 0.09, 95% CI 0.02–0.49, p =.006), and baseline serum C-reactive protein concentration (HR 1.19, 95% CI 1.07–1.32, p =.001) were independently associated with PFS. Based on these findings, baseline serum TK1 activity does not appear to be a useful prognostic biomarker in dogs with CHOP-treated DLBCL.en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.1111/vco.12876en
dc.identifier.eissn1476-5829en
dc.identifier.issn1476-5810en
dc.identifier.orcidRuple, Audrey [0000-0002-5223-0217]en
dc.identifier.pmid36651594en
dc.identifier.urihttp://hdl.handle.net/10919/114191en
dc.language.isoenen
dc.publisherWileyen
dc.relation.urihttps://www.ncbi.nlm.nih.gov/pubmed/36651594en
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectcell proliferationen
dc.subjectneoplasmsen
dc.subjectprognosisen
dc.subjectsurvivalen
dc.subjectveterinaryen
dc.subjectRare Diseasesen
dc.subjectCanceren
dc.subjectLymphomaen
dc.subjectHematologyen
dc.subjectClinical Researchen
dc.titleSerum thymidine kinase 1 activity as a prognostic biomarker in dogs with chemotherapy-treated diffuse large B-cell lymphomaen
dc.title.serialVeterinary and Comparative Oncologyen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
dc.type.otherJournal Articleen
dcterms.dateAccepted2022-12-29en
pubs.organisational-group/Virginia Techen
pubs.organisational-group/Virginia Tech/Veterinary Medicineen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/Population Health Sciencesen
pubs.organisational-group/Virginia Tech/All T&R Facultyen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/CVM T&R Facultyen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Vet Comparative Oncology - 2023 - Zaidi - Serum thymidine kinase 1 activity as a prognostic biomarker in dogs with.pdf
Size:
937.89 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

All Faculty Deposits
Scholarly Works, Population Health Sciences